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Advancement of surgery for non small cell lung cancer
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The standard operative procedure for lung cancer is lobectomy and 
mediastinal lymph nodes sampling or dissection. This concept has been 
unchanged for these 3 decades.
But detected lung cancer shifts to earlier stages and preoperative work 
up becomes more accurate than before, with development of diag-
nostic equipments. For instance, about half of resected lung cancer 
population has shifted to stage IA in Japan and population of stage III 
has decreased. This tendency comes from vast spread of high technol-
ogy CAT scan and PET scan. Early detection of lung cancer becomes 
increasing and marginal cases of stage III turned out to be stage IV with 
those developments.
In Japan, ratio of adenocarcinoma reached up to 70% in Non small cell 
lung cancer, and ratio of squamous and small cell carcinoma is decreas-
ing. We have to consider adoption of less invasive surgery for that early 
stage lung cancer. Unfortunately, a randomized trial, which was con-
ducted by Ginsberg and reported on 1995, could not show equivalence 
of limited resection to lobar resection for T1N0 lung cancer. This report 
resulted that limited resection had more frequently relapsed locally. 
Now ACOSOG conducts randomized trial of sublobar resection with 
or without brachytherapy in high risk patients with non-small cell lung 
cancer (Z4032).
From Japan, several retrospective studies about segmentectomy for 
early stage lung cancer has reported to have fair results (81-89% of 5 
year survival), comparing traditional lobectomy, although those studies 
are retrospective studies. We have to conduct a prospective study to 
conﬁrm those data. Japan Clinical Oncology Group is now planning to 
compare segmentectomy vs. lobectomy for clinical stage IA less than 
2 cm diameter, which located outer layer of the lung and has no hilar 
lymph node metastasis conﬁrming by intraoperative lymph node exam-
ination of frozen sections. We are also planning other prospective phase 
II study for wedge resection of peripherally existing non invasive type 
lung cancer, deﬁned as lesion which has more than 3 fourths of ground 
glass opacity at CT scan. Noguch et al. reported that bronchioalvelar 
type of lung cancers deﬁned as Noguch type A and B showed no hilar 
metastasis and no relapse after conventional lobectomy. We hypoth-
esized that the lesion with more than 3 fourths of ground glass opacity 
should be matched as those Noguch A or B. We have performed 
prospective analysis whether CT scan ﬁndings foresight pathological 
early lung cancer (JCOG0204). It failed to show the complete boundary 
by CT scan ﬁndings with pathological non invasiveness. At least, small 
sized lung cancer which has more than 3 fourths of ground glass opac-
ity at CT scan has no hilar and mediastinal lymph node metastasis. This 
studies primary end point is rate of 5 year surviva with local relapse 
and surgical morbidities.
There is another strategy of less invasive surgery deﬁned as video as-
sited thoracoscopic surgery. Advancement of surgical equipments and 
video systems makes VATS lobectomy more safe than before. Although 
the evolution of this technique is still slow. In Korea, several surgeons 
are now conducting feasibility studies about VATS lobectomy, which 
primary end point is morethan 90 % of safely completetion of VATS 
lobectomy.
IALT study, JBR10 and ANITA study demonstrated efﬁcacy of adju-
vant chemotherapy for completely resected non-small cell lung cancer. 
Adjuvant chemotherapy with platinum contained regimen is now 
standard of care for stage II-III. From Japan, we reported the efﬁcacy 
of UFT for completely resected stage Ib non-small cell lung cancer. But 
we still have no information whether pre or post adjuvant chemothera-
py is more effective. We do not know what kind of factors are relating 
to effectiveness of adjuvant chemotherapy. Those issues will become 
clear within several years through many translational studies.
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After approximately 20-30 years of extensive preclinical studies on 
the molecular events important in lung cancer, eventually molecularly 
targeted agents have seen some success in advanced non-small cell 
lung cancer. Two of these have already been registered (erlotinib and 
bevacizumab), and several others are under extensive investigation in 
phase III trials in different settings of the disease. The targets of the 
ﬁrst two agents to see the registration, i.e. EGFR and VEGF, are clearly 
prototypes of targets that are important in several tumors and will have 
broader applicability. Whereas targeting EGFR sensitive patients has 
become easier with the use of mutation anaysis and FISH for EGFR, 
the use of bevacizumab in combination with standard chemotherapy 
at this moment cannot be adequately targeted by a proper patient 
selection. Among novel angiogenesis inhibitors, are very many small 
molecules that target the receptors for VEGF and other molecules 
involved in angiogenesis, such as PDGFRs. Several of these agents 
are being actively tested in phase III studies (e.g. sorafenib, ZD6474) 
or large phase II studies (e.g. sunitinib, ZD2171). It is already evident 
that some of these molecules have single agent activity and although 
tehy have been tested in all NSCLC histologies (including squamous 
carcinomas), they appear to have similar toxicities as reported with 
bevacizumab (cavitation and bleeding). More extensive studies will be 
needed to unravel speciﬁc differences.
At least three “immunologically based” therapeutics are being inves-
tigated in large studies in NSCLC. BL25, a Muc-1 vaccine is being 
tested in stage III unresectable patients in a phase III trial. Recombinant 
Mage-3 has been investigated in the adjuvant setting in a large phase 
II randomized study and in proceeding into phase III. Two phase III 
studies of a Toll-9 agonist have recently been completed in advanced 
NSCLC.
A large number of other molecules are being developed in advanced 
NSCLC. Some of these will clearly have more efﬁcacy in selected 
patients than in the general population, and will likely have the best 
results in less advanced stages of the disease.
